



In vitro evaluation of gastro-intestinal digestion and colonic biotransformation of curcuminoids considering different formulations and food matrices

Papillo, V. A., Arlorio, M., Locatelli, M., Fuso, L., Pellegrini, N., & Fogliano, V.

This is a "Post-Print" accepted manuscript, which has been Published in "Journal of Functional Foods"

This version is distributed under a non-commercial no derivatives Creative Commons



(CC-BY-NC-ND) user license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and not used for commercial purposes. Further, the restriction applies that if you remix, transform, or build upon the material, you may not distribute the modified material.

Please cite this publication as follows:

Papillo, V. A., Arlorio, M., Locatelli, M., Fuso, L., Pellegrini, N., & Fogliano, V. (2019). In vitro evaluation of gastro-intestinal digestion and colonic biotransformation of curcuminoids considering different formulations and food matrices. *Journal of Functional Foods*, 59, 156-163. <https://doi.org/10.1016/j.jff.2019.05.031>

You can download the published version at:

<https://doi.org/10.1016/j.jff.2019.05.031>

1 ***In vitro* evaluation of gastro-intestinal digestion and colonic**
2 **biotransformation of curcuminoids considering different formulations**
3 **and food matrices**

4
5
6 **Valentina Azzurra Papillo^a, Marco Arlorio^a, Monica Locatelli^a, Laura Fuso^b, Nicoletta**
7 **Pellegrini^{c,d*}, Vincenzo Fogliano^d**

8
9 ^aUniversità degli Studi del Piemonte Orientale “A. Avogadro” – Dipartimento di Scienze del
10 Farmaco– Largo Donegani 2, 28100 Novara, Italy

11 ^bM.I.A.C. S.c.p.a.- Polo AGRIFOOD Regione Piemonte, Dronero (Cuneo, Italy)

12 ^c Department of Food and Drug, Human Nutrition Unit, University of Parma, Parco Area delle
13 Scienze 47/A, 43124 Parma, Italy

14 ^d Food Quality and Design Group, Wageningen University and Research Centre, P.O. Box 8129,
15 6700 EV Wageningen, The Netherlands

16
17 *Corresponding author at: Department of Food and Drug, Human Nutrition Unit, University of
18 Parma, Parco Area delle Scienze 47/A, 43124 Parma, Italy

19 e-mail address: nicoletta.pellegrini@unipr.it

20
21 **Declarations of interest:** none.

22 **Disclosure of potential conflicts of interest:** there are no conflicts of interest in this study.

23 **Abstract**

24 Pharmaceutical formulations for improving stability and bioavailability of curcuminoids are often
25 produced using excipients unsuitable for food applications. In this work, turmeric oleoresin was
26 microencapsulated by spray drying using gum arabic and maltodextrins to prepare a new ingredient
27 (GA/MD) for food industry. *In vitro* bioaccessibility and degradation of curcuminoids along the
28 gastro-intestinal tract was investigated, and compared with two commercial ingredients, turmeric
29 powder and Meriva[®]. Curcuminoids were significantly degraded under the gastro-intestinal
30 conditions in all the formulations; however, their bioaccessibility in GA/MD ingredient was 25-fold
31 higher than that of turmeric powder, but slightly lower (1.2-fold) to that of Meriva[®]. After addition
32 to rice and yoghurt, the curcuminoid bioaccessibility of GA/MD was about 2- fold higher than for
33 the ingredient alone and 1.5- fold higher than for Meriva[®]; furthermore, addition to rice improved
34 bioaccessibility more than in yogurt. Studies using different coating agents and other food matrices
35 are needed.

36 **Keywords**

37 Microencapsulation; spray-drying; food matrix effect; turmeric; bioaccessibility; Twin-SHIME[®]
38 dynamic model.

39 **1 Introduction**

40 Turmeric (*Curcuma longa* L.) is a member of *Zingiberaceae* family cultivated in tropical and subtropical
41 regions around the world. It is a rhizome extensively used as spice, traditional medicinal herb, food coloring
42 and additive (E100) (Kocaadam & Sanlier, 2017) as well as, more recently, ingredient in food supplements.
43 The main colored and bioactive compounds in turmeric are the curcuminoids: the curcumin 1,7-bis(4-
44 hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), the demethoxycurcumin and the
45 bisdemethoxycurcumin. They belong to the group of diarylheptanoids (or diphenylheptanoids) having an
46 aryl-C7-aryl skeleton (Li et al., 2011). Curcuminoids are considered the main active and abundant
47 ingredients in turmeric; it has shown antitumor, antioxidant, antimicrobial and anti-inflammatory properties
48 both in *in vitro* and in *in vivo* studies (Kocaadam et al., 2017).

49 The World Health Organization stated that the acceptable daily intake of curcuminoids as food additive is
50 in the range of 0-3 mg/kg (Amalraj, Pius, Gopi & Gopi, 2017). An average daily intake of turmeric in the
51 Indian diet (largely devoted to the use of turmeric) was estimated of approximately 60-100 mg of
52 curcuminoids (Mahmood, Zia, Zuber, Salman & Anjum, 2015).

53 Curcumin is industrially produced from turmeric oleoresin, which is a brownish-orange viscous oily
54 product extracted from the rhizome generally using a non-aqueous solvent (mainly ethanol, methanol,
55 acetone, isopropanol, dichloromethane or hexane), followed by the removal of the solvent by evaporation
56 (Jayaprakasha, Negi, Anandharamakrishnan, & Sakariah, 2001). Turmeric oleoresin is not water-soluble and
57 contains resinous material, volatile compounds, essential oils (Hastak et al., 1997) and about 30-45% (w/w)
58 of curcuminoids (Kshirsagar, Yenge, Sarkar, & Singhal, 2009), the concentration of which depends on
59 variety, agronomical practices (Li et al., 2011) and extraction methods.

60 A downside of curcumin is represented by its low stability when exposed to light, high temperature,
61 metallic ions, enzymes and oxygen (Wang, Lu, Lv, & Bie, 2009). It is also characterized by a low
62 bioavailability, related to low bioaccessibility, high rate of metabolism, rapid elimination and clearance from
63 the body (Lee et al., 2013). The low bioaccessibility, in turn, depends on very limited water-solubility (18
64 ng/mL) (Kaminaga et al., 2003), that also particularly depends on the molecular behaviour, because of the
65 keto-enol forms due to the tautomerism which is able to influence the hydrophobicity and polarity.
66 Moreover, curcuminoids are susceptible to degradation under alkaline conditions, reducing additionally the

67 bioavailability. Particularly, at pH above 7 and within thirty minutes, it degrades to trans-6-(40-hydroxy-30-
68 methoxyphenyl)-2,4-dioxo-5-hexanal, ferulic acid, feruloylmethane, and vanillin (Wang et al., 1997).
69 Conversely, under acidic conditions, the degradation of curcumin is slower, with less than 20% of total
70 curcumin decomposed in 1 h (Wang et al., 1997). Therefore, when curcumin is orally ingested, only a small
71 portion is absorbed within the intestine, metabolized and then excreted through urine (Hoehle, Pfeiffer,
72 Solyom, & Metzler, 2006). The major portion of curcumin arrives to the colon and it is partially metabolised
73 by colonic bacteria. In any case, more than 75% of curcumin is excreted in faeces (Lee et al., 2013).

74 Many physical strategies have been developed to improve stability and bioavailability of curcumin,
75 including its inclusion in liposomes (De Leo et al., 2018; Pu, Tang, Li, Li, & Sun, 2019), nanoparticles and
76 polymeric micelles, micro- and nano-emulsions (Araiza-Calahorra, Akhtar, & Sarkar, 2018) and
77 phospholipid-complexes (Liu et al., 2016). The latter approach was applied in Meriva[®], a patented
78 phytosome-like ingredient used in food supplements marketed in the USA and Europe (Belcaro et al., 2010).
79 Formulation of curcumin with adjuvants like piperine and quercetin (Anand, Kunnumakkara, Newman, &
80 Aggarwal, 2007), or with volatile oils present in oleoresin, led to an increase of curcumin absorption in
81 humans (Jager et al., 2014). Furthermore, food matrix and cooking method may affect the bioaccessibility
82 and bioavailability of curcuminoids (Zou, Liu, Liu, Xiao, & McClements, 2015; Vitaglione et al., 2012).
83 Although many formulations have been developed to increase the bioavailability of curcuminoids, they are
84 often produced for pharmaceutical and food supplement industry, using excipients unsuitable for food
85 industry.

86 In this work, the *in vitro* bioaccessibility and the degradation of curcuminoids along the gastro-intestinal
87 tract using the *in vitro* gut simulator SHIME[®] were investigated. A microencapsulated food ingredient,
88 obtained by spray drying the turmeric oleoresin with gum arabic and maltodextrins (GA/MD)¹, was
89 developed and compared with two commercial ingredients, turmeric powder and Meriva[®]. Moreover, to
90 study the matrix effect, the degradation of curcuminoids was evaluated in two model foods, plain yogurt (a
91 protein-rich food) and rice (a carbohydrate-rich food) enriched with the curcumin-based ingredients.

92

¹ Abbreviations: GA/MD, turmeric oleoresin with gum arabic and maltodextrins; GA, gum arabic; maltodextrins, MD; yogurt-GA/MD, plain yogurt enriched with GA/MD; rice-GA/MD, rice enriched with GA/MD; rice-turmeric, rice enriched with turmeric; FE-SEM, Field Emission Scanning Electron Microscope.

93 2 MATERIAL AND METHODS

94 2.1 Materials

95 The turmeric oleoresin was kindly provided by Fiorio colori SpA (Milan, Italy), while the turmeric
96 powder by MB Med srl (Turin, Italy). Meriva[®] was provided by Indena SpA (Milan, Italy). Meriva[®] was
97 obtained by mixing curcumin, soy lecithin and microcrystalline cellulose in a 1:2:2 weight ratio, through the
98 Phytosome[®] strategy, to improve the curcumin bioavailability. The plain yogurt and the rice variety
99 “carnaroli” were purchased at the supermarket. Ethanol, formic acid, acetonitrile, gum arabic (GA), and all
100 analytical standards (curcumin, demethoxycurcumin and bisdemethoxycurcumin) were purchased from
101 Sigma Aldrich (St. Louis, MO, USA), while maltodextrins (MD) (dextrose equivalent 16-20%) was obtained
102 from A.C.E.F. (Fiorenzuola d’Arda, Italy). The enzymes pepsin (3600 U/mg) from porcine gastric mucosa,
103 pancreatin (8 × USP) from porcine pancreas and porcine bile extract were purchased from Sigma-Aldrich
104 (Milan, Italy).

105

106 2.2 Microencapsulation of oleoresin by spray drying

107 Turmeric oleoresin was microencapsulated with *food grade* wall materials in a 95:5 (w/w) ratio of GA
108 and MD mixture and oleoresin, to obtain the microencapsulated ingredient (GA/MD). This
109 microencapsulation was done to improve the water-solubility, stability and bioaccessibility of turmeric
110 oleoresin.

111 The GA and MD mixture, in a 80:20 (w/w) ratio, was dispersed in water at 60 °C, with magnetic stirring
112 until complete hydration, to a final concentration of 20% (w/v), and then kept in fridge overnight.

113 Turmeric oleoresin was solubilized in ethanol at a concentration of 2% (w/v) and kept in constant
114 agitation for 1 h at room temperature in the dark. Once solubilized, it was added, dropwise, to the dispersion
115 of wall materials, in a constant stirring at 1000 rpm for 10 min, then mixed using a rotor-stator homogenizer
116 Ultra-Turrax[®] T25 Basic (Ika-Werke GmbH, Staufen, Germany) at 13500 rpm for 2 min and finally
117 sonicated for 10 min in an ultrasonic bath to obtain a fine emulsion (Sari et al., 2015).

118 The spray-drying of the emulsion was obtained using the Mini Spray Dryer B-290 (Büchi[®], Switzerland)
119 and was performed at inlet and outlet temperature of 130 °C and 80 °C, with a feed flow of 7 mL/min and
120 airflow of 40 m³/h.

121 The encapsulation yield, calculated as the ratio percentage between the weight of microencapsulated
122 powder and the theoretical weight of powder (turmeric oleoresin, GA and MD), was 65%.

123

124 **2.3 Water Solubility Index (WSI)**

125 The WSI of curcuminoids in oleoresin, GA/MD, Meriva[®] and turmeric was determined modifying the
126 method described by Kha, Nguyen, & Roach (2010). Saturated solutions of the ingredients were
127 vigorously kept in stirring for 24 h at room temperature and then filtered with 0.45 µm filters (Millipore,
128 Bedford, MA). The filtered solutions were diluted with ethanol and analyzed by HPLC.

129

130 **2.4 Field Emission Scanning Electron Microscope**

131 The analysis and the morphological characterization of the powdered material produced in this study was
132 performed using a high-resolution system of Scanning Electron Microscopy. Regarding the metallization, the
133 samples were mounted on aluminium stubs with double-sided carbon sticky-tape, sputtered with chrome in a
134 vacuum evaporator and visualized using a ZEISS-SUPRA 25 Field Emission Scanning Electron Microscope
135 (FE-SEM).

136

137 **2.5 Formulation of foods enriched with curcuminoid-rich ingredients**

138 The ingredients were added to two model foods, plain yogurt and rice, at a curcuminoid concentration of
139 0.05% (w/w).

140 The plain yogurt was enriched with only GA/MD (yogurt-GA/MD), because the other two ingredients
141 (Meriva[®] and turmeric) did not dissolve in this medium. To obtain a homogeneous sample, the yogurt was
142 kept in magnetic stirring, and when the ingredient was dissolved, the sample was treated with the rotor-stator
143 homogenizer at 13500 rpm for 2 min. An aliquot of plain yogurt was used as control.

144 The rice was enriched with GA/MD (rice-GA/MD) and turmeric (rice-turmeric) to compare a commercial
145 food ingredient to the microencapsulated one. One hundred grams of rice were cooked in 600 mL of boiling
146 water for 14 min. The initial volume of water was determined prior to the experiment as to guarantee that at
147 the end of cooking all the water was absorbed by the rice. The cooked rice was divided in three parts: one

148 was added with the ingredient GA/MD, one with turmeric and one represented the control (white rice). These
149 rice samples were then roughly grinded to simulate the human mastication.

150

151 **2.6 *In vitro* digestion**

152 To evaluate the *in vitro* bioaccessibility of curcuminoids, the standard INFOGEST protocol (Minekus et
153 al., 2014) was applied to ten grams of food (yogurt-GA/MD, rice-GA/MD and rice-turmeric), 500 mg of
154 GA/MD, 250 mg of turmeric and 25 mg of Meriva[®], corresponding to 5 mg of curcuminoids. Salivary
155 amylase (75 U/mL), pepsin (2000 U/mL), pancreatin (corresponding to a trypsin activity of 100 U/mL) with
156 bile salt (10 mM) were used to simulate oral, gastric and intestinal digestion. Samples were digested in
157 triplicate. At the end of each digestive step, one milliliter of digested sample was collected, and the same
158 fractions (stomach and small intestine) of three separate digestions were combined and mixed. The analyses
159 were performed on the combined samples.

160

161 2.6.1 Determination of *in vitro* bioaccessibility

162 Concerning the intestinal digestion, an aliquot of the sample was further centrifuged at 2300 x g for 5
163 min at 4 °C to separate the soluble (supernatant) and insoluble (pellet) fraction in order to quantify their
164 individual curcuminoid content. The curcuminoid content was determined following protocols described at
165 sections 2.8.4 and 2.9.

166 The bioaccessibility index of curcuminoids at small intestinal phase was calculated as follows (Ortega,
167 Reguant, Romero, Macia, & Motilva, 2009):

$$168 \frac{\text{Total curcuminoids in soluble fraction}}{\text{Total curcuminoids in digested sample (soluble + insoluble fractions)}} \times 100$$

169

170 **2.7 Twin-SHIME[®]**

171 The Simulator of Human Intestinal Microbial Ecosystem (SHIME[®]) was used to simulate the three tracts
172 of colon: ascending, transverse and descending using the settings previously described (Possemiers, Verthé,
173 Uyttendaele, & Verstraete, 2004).

174 It was set up using two vessels for each tract (Twin-SHIME[®]) and all vessels were inoculated with the
175 same faecal sample of a healthy human volunteer and stabilized over 2 weeks as previously described (Koper
176 et al., 2018). Inoculum was prepared from freshly voided faecal samples diluted 10-fold in 0.1 M phosphate
177 pH = 7.0 with 1 g/L sodium thioglycolate and centrifuged briefly to remove particulates. SHIME[®] was fed
178 three times a day with 200 mL of a solution composed of: 1 g/L arabinogalactan, 2 g/L pectin, 1 g/L xylan, 3
179 g/L potato starch, 0.4 g/L glucose, 3 g/L yeast extract, 1 g/L pepton, 4 g/L mucin and 0.5 g/L cysteine. The
180 pH of the feed was set to 2 and the feed was stored at 4 °C before incubation in each vessel.

181 The parameters of Twin-SHIME[®] vessels were: pH 5.6-5.9, volume 500 mL for the ascending vessel; pH
182 6.1–6.4, volume 800 mL for the trasverse vessel; pH 6.6–6.9, volume 600 mL for descending vessel. The
183 system was kept at 37 °C and in anaerobic conditions by flushing it daily with N₂.

184 In order to evaluate the curcuminoids degradation by the colonic bacteria, single ingredients and
185 undigested insoluble fractions of rice collected after *in vitro* digestion (see paragraph 2.6.1) were added in a
186 right amount to have the same curcuminoid concentration (5 µg/mL) in each vessel. To allow the transfer in
187 the vessels, samples were firstly hydrated with 2 mL of water. To evaluate the microbial biotransformation
188 over time (5 h), 5 mL of each vessel content were collected at 0, 10, 25, 50, 75, 100, 150, 225 and 300 min,
189 for a total of 9 aliquots. Samples were stored at –20 °C until the analysis.

190

191 **2.8 Extraction of curcuminoids**

192 2.8.1 Extraction of curcuminoids from the ingredients

193 Fifty milligrams of GA/MD ingredient were firstly hydrated with 400 µL of water by vortex, extracted
194 with 1600 µL of ethanol, sonicated for 10 min and centrifuged at 20800 *x g* for 10 min at 4 °C. The
195 supernatant was conveniently diluted and analyzed.

196 One milligram of turmeric was extracted with 1 mL of ethanol/water 80:20 (v:v), sonicated for 5 min and
197 centrifuged at 20800 *x g* for 10 min. The pellet was further extracted with 1 mL of ethanol, sonicated for 5
198 min and centrifuged. The two supernatants were combined, diluted and analyzed.

199 One milligram of Meriva[®] was extracted with 1 mL of ethanol/water 80:20 (v:v), sonicated for 5 min and
200 centrifuged at 20800 *x g* for 10 min. The supernatant was diluted and analyzed.

201

202 2.8.2 Extraction of curcuminoids from the yogurt

203 Five hundred milligrams of yogurt were extracted firstly with 1.5 mL ethanol, mixed by vortex for 1
204 min, sonicated for 5 min and then centrifuged at 20800 x g for 5 min. 1.5 mL of ethanol/water (80:20 v/v)
205 were further added to the residual pellet, sonicated for 5 min and subsequently centrifuged. This step was
206 performed twice and, finally, the three supernatants were combined, diluted and analyzed.

207

208 2.8.3 Extraction of curcuminoids from the cooked rice

209 One hundred milligrams of cooked rice were extracted firstly with 1.5 mL ethanol/water (80:20 v/v) in
210 agitation for 5 min and then centrifuged at 2300 x g for 5 min. The supernatant was removed. Afterward, 3
211 mL of ethanol/water (80:20 v/v) were added to the residual pellet, sonicated for 5 min and subsequently
212 centrifuged. The two supernatants were collected, centrifuged at 20800 x g for 5 min, diluted conveniently
213 and analyzed.

214

215 2.8.4 Extraction of curcuminoids from digested samples

216 The curcuminoids were extracted from the entire digested samples (i.e., foods and ingredients) at the end
217 of each digestive step (stomach and small intestine) in order to evaluate the eventual degradation of
218 curcuminoids following the digestion phases. In the case of the pancreatic digestion, digested samples were
219 further centrifuged to separate soluble and insoluble fractions, thus permitting to determine the *in vitro*
220 bioaccessibility (see section 2.6.1).

221 One hundred milligrams of entire digested sample were extracted with 2 mL of ethanol, mixed for 5 min
222 and centrifuged at 20800 x g for 5 min. The supernatant was diluted and analyzed.

223 The soluble fraction after pancreatic digestion (500 μ L) was treated with 0.5 mL of ethanol and mixed
224 for 5 min. The sample was then centrifuged at 20800 x g for 5 min and then analyzed.

225 The insoluble fraction after pancreatic digestion was extracted by adding 3 mL of ethanol to 0.1 g of
226 pellet, mixed for 5 min and centrifuged at 2300 x g for 5 min. After that, the pellet was extracted again with 2
227 mL of ethanol in an ultrasonic bath for 10 min, then centrifuged at 20800 x g for 5 min. The two supernatants
228 were combined before the analysis.

229

230 2.8.5 Extraction of curcuminoids after colonic fermentation

231 The extraction of curcuminoids from 0.5 mL of sample incubated in the Twin-SHIME system was
232 preceded by a step of centrifugation at 20800 $x g$ for 5 min at 4 °C. Subsequently, the supernatant was
233 eliminated, and the pellet was extracted with 0.5 mL of ethanol, vortexed and sonicated for 10 min. The
234 sample was then centrifuged at 20800 $x g$ for 5 min at 4 °C and the supernatant analyzed.

235

236 **2.9 HPLC analysis**

237 The determination of curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) was
238 performed by the method described by Tan et al. (2015) slightly modified. The apparatus was a Thermo
239 Finnigan Surveyor HPLC System (Thermo Scientific, MA, USA) equipped with a photodiode array (PDA)
240 detector. Separation was performed on a reversed-phase Xbridge Shield 18 column (100 mm x 2.1, 3.5 μm ;
241 Waters, Massachusetts, USA). The eluents were: (A) acidified acetonitrile (0.1% formic acid, v/v) and (B)
242 acidified water (0.1% formic acid, v/v). The gradient program was: 0-5 min, 95-65 % B; 5-30 min, 65-50 %
243 B; 30-31 min, 50-0 % B; 31-35 min, 0% B; 35-45 min, 0-95%; 45-51 min, 95% B. The flow rate of mobile
244 phase was 0.5 mL/min and the column temperature of 30 °C. The injection volume was 5 μL .

245 Chromatograms were recorded at 425 nm. All compounds were identified comparing retention time and
246 UV/Vis spectra of each respective standard. Calibration curves of each compound, at six different
247 concentration levels, were used for the quantification. Validation parameters of calibration curves are
248 reported as Supplementary Material (Table S1). Results were expressed as total curcuminoids, calculated as
249 sum of the three curcuminoids.

250

251 **2.10 Statistical analysis**

252 Results were reported as mean \pm standard deviation of at least three experiments, excepting for SHIME
253 experiments, for which the analyses were performed in duplicate. The significance of differences was
254 determined by ANOVA, followed by Tukey's post hoc test ($p < 0.05$) using XLStat 365 (Addinsoft, Paris,
255 France).

256

257 **3 RESULTS AND DISCUSSION**

258 **3.1 HPLC characterization of ingredients and oleoresin**

259 Turmeric oleoresin, the microencapsulated ingredient (GA/MD) and the two commercial products
260 (turmeric and Meriva[®]) were characterized for their curcuminoids content by HPLC-PDA (**Table 1**). The
261 microencapsulated ingredient and the oleoresin showed a similar composition: 65% of curcumin, 17% of
262 demethoxycurcumin and 18% of bisdemethoxycurcumin. However, the concentration of total curcuminoids
263 in the microencapsulated ingredient (1% w/w) was 24-fold less than that of oleoresin, and half of that in
264 turmeric powder, which had a slightly different composition (71%, 16% and 12% of curcumin,
265 demethoxycurcumin and bisdemethoxycurcumin, respectively). This result is in accord with many previous
266 observations, reporting a significant variability in terms of total content of curcuminoids in different sources
267 (turmeric powder, oleoresins, concentrated products) as well as in terms of composition (relative percentage
268 of curcuminoids). Moreover, the curcuminoids content of the raw material (*Curcuma longa* botanical) as
269 well as the environmental parameters can affect the expression and accumulation of bioactive substances
270 (both regarding total volatiles and total non-volatiles compounds) in turmeric (Souza & Glória, 1998). The
271 curcuminoids content of GA/MD was partially affected by the microencapsulation process through spray-
272 drying. In particular, we determined that the encapsulation efficiency of GA/MD, calculated as the
273 percentage ratio between the curcuminoids content determined by HPLC and their theoretic content, was
274 83%. In a previous work, the encapsulation efficiency of curcumin in microcapsules obtained by spray-
275 drying using a similar blend of coating agent (GA/MD 80:20 supplemented with 1% pullulan) was 65%
276 (Kshirsagar et al., 2009).

277 The WSI of the turmeric-based ingredients was measured as total curcuminoids concentration in a saturated
278 aqueous solution. The microencapsulated ingredient showed the highest WSI (82 µg/mL), resulting in
279 concentration about 40-fold higher than Meriva[®] and turmeric (2.1 and 1.8 µg/mL, respectively). Oleoresin
280 was insoluble and no curcuminoids were detected in its aqueous solution. These results are in agreement
281 with our expectations; in fact, GA/MD was prepared using hydrophilic polymers in order to increase the
282 water solubility of curcuminoids. On the other hand, Meriva[®] is formulated in a phospholipidic matrix (soy

283 lecithin), which improves the *in vivo* bioavailability of curcuminoids, but it is not soluble in water.

284 Therefore, the very low WSI of Meriva[®] was also expected.

285 **3.2 Morphological analysis of the microencapsulated ingredient**

286 The powdered ingredient GA/MD was characterized in the surface/inner morphology and size of
287 microspheres. FE-SEM analysis showed differently sized microspheres often aggregated in agglomerates, a
288 phenomenon probably also due to the hygroscopic nature of wall material (**Figure 1**). The dimensions
289 ranged from 1 to 15 μm . The smallest microspheres had a dented and collapsed surface, attributable to the
290 partial shrinkage of the particles during the drying process, while the biggest ones showed breakages on the
291 surface and seemed to be a collection of more microspheres. In a previous work, Cano-Higueta, Malacrida,
292 and Telis (2015) observed that microcapsuled particles prepared with GA (alone or associated with MD and
293 modified starch) had generally smooth and continuous surfaces, but in some cases presented dent formation,
294 indicating shrinkage. Collapsed particles are probable related to empty particles, without any inclusion of
295 oleoresins dissolved in ethanol during preparation. Moreover, looking at the morphology of the
296 microspheres, as well as the inner structure visible across the smooth thin transparent surface, a porous
297 structure can be easily highlighted. The porous matrix can be generated by the evaporation of the ethanol at
298 high temperature during the spray-drying process. As generally accepted, this typology of matrix can
299 improve significantly the contact with the aqueous solvent, which depends on the increase of the total area of
300 the surface, leading the improvement of the hydrophilic properties, as highlighted during the bioaccessibility
301 tests (see below). Indeed, porous microspheres had interconnective external and internal pores leading to
302 very low mass density and enormous specific surface area, enabling them to have excellent adsorption
303 capabilities (Dastidar, Saha & Chowdhury, 2018). Moreover, this porous system can dramatically improve
304 the dissolution rates of biomolecules in hydrophilic medium, allowing the microspheres work as functional
305 microcarrier for the *in vivo* delivery of bioactive compounds (Ebrahimi, Saffari & Langrish, 2017).

306 Other studies on curcumin encapsulation confirmed the possibility to obtain also nanoparticles with
307 interesting properties (e.g. enhanced antimicrobial properties), reaching a narrow particle size distribution in
308 the range of 2-40 nm. The nanodimension of these materials can strongly improve their dispersibility in
309 water, as observed in the case of microspheres prepared in this work. The enhanced antimicrobial properties
310 of these nanoparticles containing curcumin when compared to raw oleoresin is explained by their capacity to

311 be integrated in the microbial cell of GRAM+ and GRAM- bacterial strains. This effect must be deeply
312 studied *in vivo*, considering the chance to interact with the gut microbiota (Basniwal, Buttar, Jain & Jain,
313 2011).

314

315 **3.3 Degradation of curcuminoids in curcuminoid-rich ingredients along the gastro-intestinal** 316 **tract**

317 GA/MD, turmeric and Meriva[®] underwent an *in vitro* digestion to evaluate the curcuminoids
318 degradation, in different formulations, at physiological conditions (pH, temperature and enzymes). The total
319 curcuminoids of each formulation before digestion (undigested ingredient), and after the gastric (pepsin) and
320 the intestinal phase (pancreatin) are displayed in **Table 2**. A significant decrease in the amount of
321 curcuminoids in all the ingredients was measured at the end of the two digestion phases. The highest
322 decrease was observed during intestinal phase in GA/MD (-32%), whereas a similar and lower decrease was
323 measured for turmeric and Meriva[®] (-16% and -17%, respectively). GA/MD had the highest loss already in
324 the gastric phase (-20%), when compared to turmeric (-14%) and Meriva[®] (-9%). Similar results were
325 observed by Aniesrani Delfiya, Thangavel, Natarajan, Kasthuri, and Kailappan (2015), who highlighted that
326 the curcuminoids microencapsulated with GA were released more quickly in an acid medium than those
327 present in oleoresin because of the fast hydrolysis of curcumin-GA bond. Meriva[®] was the formulation that
328 showed the highest stability to the gastro-intestinal conditions. This was likely due to the presence of
329 phospholipids that protect the sensitive active agents from the degradation (Fricker et al., 2010). Based on all
330 these observations, we can hypothesize that the high curcuminoids degradation in GA/MD following
331 digestion is to be related to the hydrophilic properties of coating agents, which have also contributed to the
332 the highest WSI value of GA/MD (**Table 1**).

333 To determinate the bioaccessible fraction of total curcuminoids, the digested samples were separated by
334 centrifugation in two fractions, soluble (bioaccessible) and insoluble (non-bioaccessible). **Figure 2** shows the
335 percentage of soluble and insoluble curcuminoids in GA/MD, Meriva[®] and turmeric, expressed with respect
336 to their total content after digestion. The obtained values highlight a higher bioaccessibility in the ingredients
337 GA/MD (4.9 ± 0.7) and Meriva[®] (5.7 ± 0.5), in which the curcuminoids are embedded into a lipophilic
338 phospholipid environment able to form micro-emulsion (Ahmed, Li, McClements, & Xiao, 2012; Zou et al.,

339 2015), compared to the turmeric powder (0.18 ± 0.05). It is also interesting to observe that, despite their
340 dramatically different WSI, GA/MD and Meriva[®] present very similar bioaccessibility. Gum arabic and
341 maltodextrins are polymers characterized by high-water solubility that leads to the dissolution of
342 curcuminoids in the simulated gastro-intestinal fluids. Instead, Meriva[®] is formulated with phospholipids
343 (soy lecithin), which have very low water solubility, but can be digested by pancreatic lipases, thus releasing
344 curcuminoids in the digestion medium. For this reason, they have similar bioaccessibility.

345 The degradation of curcuminoids in each section of the colon was investigated by incubating the three
346 ingredients with the microbiota present in the three different SHIME[®] compartment. The initial concentration
347 of total curcuminoids for each sample was the same in each vessel ($5 \mu\text{g/mL}$). The degradation of total
348 curcuminoids in each colon section is showed in **Figure 3**.

349 To the best knowledge of the authors, this is the first time the degradation of curcuminoids was studied
350 in each single section of a human colon simulator. After 5 h of incubation, the loss of curcuminoids was
351 about one third in the ascending colon (29% for Meriva[®], 33% for GA/MD and 37% for turmeric). In the
352 transverse colon, the loss ranged from 34% in Meriva[®] to 60% in turmeric. In the descending colon, there
353 was the highest loss ranging from 46% (Meriva[®]) to 61% (turmeric). Overall, Meriva[®] displayed the highest
354 stability to microbial biotransformation in each colon section when compared to the other ingredients,
355 followed by GA/MD and turmeric. The higher degradation of curcuminoids in the last section of colon was
356 probably due to the higher pH of this colon section with respect to the other ones.

357

358 **3.4 Evaluation of food matrix effect on the degradation of curcuminoids along gastro-** 359 **intestinal tract**

360 To evaluate the food matrix effect on the degradation of curcuminoids along the gastro-intestinal tract, the
361 yogurt and the rice enriched with curcuminoid-rich ingredients (rice-GA/MD, rice-turmeric and yogurt-
362 GA/MD) were underwent the same protocol of simulated digestion. The results showed in **Table 3** highlight
363 that the gastric degradation of curcuminoids in the yogurt (-10%) is lower if compared to that occurring in
364 the rice (-17% for rice-GA/MD and -19% for rice-turmeric), but these differences disappeared after the
365 intestinal digestion.

366 The results of bioaccessibility (**Fig. 4**) show a content of curcuminoids higher in the soluble fraction of
367 rice samples (6% and 9% for rice-turmeric and rice-GA/MD, respectively) compared to yogurt (1.3%), with
368 a bioaccessibility about 7 times higher for rice-GA/MD when compared to yogurt-GA/MD.

369 Interestingly, the solubility of curcuminoids increased when the ingredients were added to the rice
370 compared to when they were digested alone; particularly, the bioaccessibility increased almost 2 times for
371 GA/MD, and 30 times for turmeric. These results demonstrated the positive effect of the presence of rice
372 matrix on the bioaccessibility of curcuminoids. A similar result was observed in a clinical trial by Vitaglione
373 et al. (2012). The authors demonstrated that the curcuminoids encapsulated with cellulose derivates and
374 vegetable oil and provided in a carbohydrate-based food (i.e. bread) were more bioavailable compared to the
375 non-encapsulated ones.

376 The bioaccessible fraction of yogurt-GA/MD was instead just the 1.3%. This result was unexpected since
377 it has been demonstrated that the presence of emulsified lipids (like fats in a plain yoghurt) increases the
378 bioaccessibility of curcumin with respect to the presence of non-emulsified ones (Zou et al., 2015). Probably,
379 the curcuminoids had a major affinity with yogurt lipids that favored the passage of curcuminoids in the
380 insoluble fraction during the step of centrifugation, while during the *in vivo* digestion they are entrapped in
381 micelles that increased their bioaccessibility and absorption (Fu, Augustin, Sanguansri, Shen, Ng &
382 Ajlouni, 2016).

383 The GA/MD enriched rice was also tested in the SHIME[®] system. The rice-turmeric was used as the
384 control since we would investigate whether the new ingredient (i.e., GA/MD) had a different behaviour with
385 respect to the traditional one (i.e., curcumin). After the gastro-intestinal digestion of rice-GA/MD and rice-
386 turmeric, their insoluble fractions underwent 5 h colonic fermentation in the ascending, transverse and
387 descending colon section (**Fig. 5**). As previously observed for the ingredients alone, the curcuminoid
388 degradation was lower for the enriched rice in the ascending colon than in the other two tracts. The
389 percentage of decrease was 34%, 44% and 49% for rice-GA/MD, and 26%, 52% and 55% for rice-turmeric
390 in ascending, transverse and descending colon, respectively.

391 Overall, even if the curcuminoids degradation by the colonic bacteria appeared slightly higher when the
392 ingredients were alone compared to when they were added to rice, no statistically significant differences
393 were found.

394

395 **4 Conclusions**

396 Low bioaccessibility and stability of curcuminoids limit the beneficial properties of turmeric. In this
397 study, we investigated the effect of a microencapsulation with food grade wall materials of turmeric
398 oleoresin on the *in vitro* bioaccessibility and microbial biotransformation of curcuminoids, and compared
399 them to the non-encapsulated commercial ingredient (turmeric) and to a patented ingredient for
400 pharmaceutical uses (Meriva®).

401 The curcuminoids were significantly degraded from the gastro-intestinal conditions in all formulations.
402 However, the curcuminoid *in vitro* bioaccessibility in the microencapsulated ingredient (i.e. GA/MD)
403 resulted 25-fold higher than that of turmeric powder. The porous microspheres are described as promising
404 carriers for bioactive compounds, particularly regarding aqueous food systems. Moreover, the curcuminoid
405 bioaccessibility of rice enriched with the spray-dried ingredient was about 2- and 1.5- fold higher with
406 respect to that of the ingredient alone and of Meriva®, respectively. Unexpectedly, curcuminoids were more
407 bioaccessible in rice than in yoghurt and the rice matrix protected the curcuminoids from their bacterial
408 degradation that occurs during the transit in the three tracts of a human colon simulator.

409 In future, further studies will be needed to evaluate the performances of the formulated microencapsulated
410 ingredient in other food matrices, like those containing phospholipids (eggs or vegetable oils). Moreover, the
411 contribution of other food grade wall materials to the gastro-intestinal stability of the main compounds
412 should be studied as well. Finally, it is worth to notice the use of these nanomaterials in Europe is currently
413 restricted, and this is a severe limitation to the exploitation of this kind of the curcumin-containing
414 ingredients.

415

416 **Acknowledgements**

417 The authors are grateful to Dr. Lorena Segale (Dipartimento di Scienze del Farmaco and APTSol Srls,
418 Novara, Italy) for her useful suggestions in the interpretation of FE-SEM images. VAP thanks the PhD
419 School of Università del Piemonte Orientale (Chemistry and Biology course) for the financial support to her
420 stay at Wageningen University.

421

422 **Formatting of funding sources**

423 This research did not receive any specific grant from funding agencies in the public, commercial, or not-
424 for-profit sectors.

425

426 **References:**

- 427 Ahmed, K., Li, Y., McClements, D. J., & Xiao, H. (2012). Nanoemulsion-and emulsion-based
428 delivery systems for curcumin: encapsulation and release properties. *Food Chemistry*,
429 *132*(2), 799-807.
- 430 Amalraj, A., Pius, A., Gopi, S., & Gopi, S. (2017). Biological activities of curcuminoids, other
431 biomolecules from turmeric and their derivatives—A review. *Journal of Traditional and*
432 *Complementary Medicine*, *7*(2), 205-233.
- 433 Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of
434 curcumin: problems and promises. *Molecular Pharmaceutics*, *4*(6), 807-818.
- 435 Aniesrani Delfiya, D., Thangavel, K., Natarajan, N., Kasthuri, R., & Kailappan, R. (2015).
436 Microencapsulation of turmeric oleoresin by spray drying and in vitro release studies of
437 microcapsules. *Journal of Food Process Engineering*, *38*(1), 37-48.
- 438 Araiza-Calahorra, A., Akhtar, M., & Sarkar, A. (2018). Recent advances in emulsion-based delivery
439 approaches for curcumin: From encapsulation to bioaccessibility. *Trends in Food Science &*
440 *Technology*, *71*, 155-169.
- 441 Basniwal, R. K., Buttar, H. S., Jain, V. K., & Jain, N. (2011). Curcumin nanoparticles: preparation,
442 characterization, and antimicrobial study. *Journal of Agricultural and Food*
443 *Chemistry*, *59*(5), 2056-2061.
- 444 Belcaro, G., Cesarone, M. R., Dugall, M., Pellegrini, L., Ledda, A., Grossi, M. G., Togni, S. &
445 Appendino, G. (2010). Product-evaluation registry of Meriva®, a curcumin-
446 phosphatidylcholine complex, for the complementary management of
447 osteoarthritis. *Panminerva Medica*, *52*(2 Suppl 1), 55-62.
- 448 Cano-Higueta, D. M., Malacrida, C. R., & Telis, V. R. N. (2015). Stability of curcumin
449 microencapsulated by spray and freeze drying in binary and ternary matrices of
450 maltodextrin, gum arabic and modified starch. *Journal of Food Processing and*
451 *Preservation*, *39*(6), 2049-2060.

452 Dastidar, D. G., Saha, S., & Chowdhury, M. (2018). Porous microspheres: synthesis,
453 characterisation and applications in pharmaceutical & medical fields. *International Journal*
454 *of Pharmaceutics*, 548(1), 34-48.

455 De Leo, V., Milano, F., Mancini, E., Comparelli, R., Giotta, L., Nacci, A., ... & Catucci, L. (2018).
456 Encapsulation of curcumin-loaded liposomes for colonic drug delivery in a ph-responsive
457 polymer cluster using a ph-driven and organic solvent-free process. *Molecules*, 23(4), 739.

458 Ebrahimi, A., Saffari, M., & Langrish, T. (2017). Improving the dissolution rate of hydrophobic
459 drugs through encapsulation in porous lactose as a new biocompatible porous
460 carrier. *International Journal of Pharmaceutics*, 521(1-2), 204-213.

461 Fu, S., Augustin, M. A., Sanguansri, L., Shen, Z., Ng, K., & Ajlouni, S. (2016). Enhanced
462 bioaccessibility of curcuminoids in buttermilk yogurt in comparison to curcuminoids in
463 aqueous dispersions. *Journal of Food Science*, 81(3), H769-H776.

464 Fricker, G., Kromp, T., Wendel, A., Blume, A., Zirkel, J., Rebmann, H., Setzer, C., Quinkert, R. O.,
465 Martin, F., & Muller-Goymann, C. (2010). Phospholipids and lipid-based formulations in
466 oral drug delivery. *Pharmaceutical Research*, 27(8), 1469-1486.

467 Hastak, K., Lubri, N., Jakhi, S. D., More, C., John, A., Ghaisas, S. D., & Bhide, S. V. (1997). Effect
468 of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral
469 submucous fibrosis. *Cancer Letters*, 116(2), 265-269.

470 Hoehle, S. I., Pfeiffer, E., Solyom, A. M., & Metzler, M. (2006). Metabolism of curcuminoids in
471 tissue slices and subcellular fractions from rat liver. *Journal of Agricultural and Food*
472 *Chemistry*, 54(3), 756-764.

473 Jäger, R., Lowery, R. P., Calvanese, A. V., Joy, J. M., Purpura, M., & Wilson, J. M. (2014).
474 Comparative absorption of curcumin formulations. *Nutrition Journal*, 13(1), 11.

475 Jayaprakasha, G. K., Negi, P. S., Anandharamakrishnan, C., & Sakariah, K. K. (2001). Chemical
476 composition of turmeric oil - A byproduct from turmeric oleoresin industry and its

477 inhibitory activity against different fungi. *Zeitschrift Fur Naturforschung C-a Journal of*
478 *Biosciences*, 56(1-2), 40-44.

479 Kaminaga, Y., Nagatsu, A., Akiyama, T., Sugimoto, N., Yamazaki, T., Maitani, T., & Mizukami,
480 H. (2003). Production of unnatural glucosides of curcumin with drastically enhanced water
481 solubility by cell suspension cultures of *Catharanthus roseus*. *FEBS Letters*, 555(2), 311-
482 316.

483 Kha, C. K., Nguyen, M. H., & Roach, P. D. (2010). Effects of spray drying conditions on the
484 physicochemical and antioxidant properties of the Gac (*Momordica cochinchinensis*) fruit
485 aril powder. *Journal of Food Engineering*, 98(3), 385-392.

486 Kocaadam, B., & Sanlier, N. (2017). Curcumin, an active component of turmeric (*Curcuma longa*),
487 and its effects on health. *Critical Reviews in Food Science and Nutrition*, 57(13), 2889-
488 2895.

489 Koper, J.E.B., Loonen, L.M.P., Wells, J.M., Troise, A.D., Capuano, E., & Fogliano, V. (2019)
490 Polyphenols and tryptophan metabolites activate the aryl hydrocarbon receptor in an in vitro
491 model of colonic fermentation. *Molecular Nutrition and Food Research*, 63(3). doi:
492 10.1002/mnfr.201800722

493 Kshirsagar, A. C., Yenge, V. B., Sarkar, A., & Singhal, R. S. (2009). Efficacy of pullulan in
494 emulsification of turmeric oleoresin and its subsequent microencapsulation. *Food*
495 *Chemistry*, 113(4), 1139-1145.

496 Lee, W. H., Loo, C. Y., Bebawy, M., Luk, F., Mason, R. S., & Rohanizadeh, R. (2013). Curcumin
497 and its derivatives: their application in neuropharmacology and neuroscience in the 21st
498 century. *Current Neuropharmacology*, 11(4), 338-378.

499 Li, S., Yuan, W., Deng, G., Wang, P., Yang, P., & Aggarwal, B. B. (2011). Chemical composition
500 and product quality control of turmeric (*Curcuma longa* L.). *Pharmaceutical Crops*, 2(1).

501 Liu, W., Zhai, Y., Heng, X., Che, F. Y., Chen, W., Sun, D., & Zhai, G. (2016). Oral bioavailability
502 of curcumin: problems and advancements. *Journal of Drug Targeting*, 24(8), 694-702.

503 Mahmood, K., Zia, K. M., Zuber, M., Salman, M., & Anjum, M. N. (2015). Recent developments in
504 curcumin and curcumin based polymeric materials for biomedical applications: a
505 review. *International Journal of Biological Macromolecules*, *81*, 877-890.

506 Minekus, M., Alming, M., Alvito, P., Ballance, S., Bohn, T., Bourlieu, C., Carriere, F., Boutrou,
507 R., Corredig, M., Dupont, D., Dufour, C., Egger, L., Golding, M., Karakaya, S., Kirkhus, B.,
508 Le Feunteun, S., Lesmes, U., Macierzanka, A., Mackie, A., Marze, S., McClements, D. J.,
509 Menard, O., Recio, I., Santos, C. N., Singh, R. P., Vegarud, G. E., Wickham, M. S.,
510 Weitschies, W., & Brodkorb, A. (2014). A standardised static in vitro digestion method
511 suitable for food - an international consensus. *Food & Function*, *5*(6), 1113-1124.

512 Ortega, N., Reguant, J., Romero, M. P., Macia, A., & Motilva, M. J. (2009). Effect of fat content on
513 the digestibility and bioaccessibility of cocoa polyphenol by an in vitro digestion model.
514 *Journal of Agricultural and Food Chemistry*, *57*(13), 5743-5749.

515 Possemiers, S., Verthé, K., Uyttendaele, S., & Verstraete, W. (2004). PCR-DGGE-based
516 quantification of stability of the microbial community in a simulator of the human intestinal
517 microbial ecosystem. *FEMS Microbiology Ecology*, *49*, 495-507.

518 Pu, C., Tang, W., Li, X., Li, M., & Sun, Q. (2019). Stability enhancement efficiency of surface
519 decoration on curcumin-loaded liposomes: Comparison of guar gum and its cationic
520 counterpart. *Food Hydrocolloids*, *87*, 29-37.

521 Sari, T., Mann, B., Kumar, R., Singh, R., Sharma, R., Bhardwaj, M., & Athira, S. (2015).
522 Preparation and characterization of nanoemulsion encapsulating curcumin. *Food*
523 *Hydrocolloids*, *43*, 540-546.

524 Souza, C. R., & Glória, M. B. A. (1998). Chemical analysis of turmeric from Minas Gerais, Brazil
525 and comparison of methods for flavour free oleoresin. *Brazilian Archives of Biology and*
526 *Technology*, *41*(2).

527 Tan, S., Calani, L., Bresciani, L., Dall'asta, M., Faccini, A., Augustin, M. A., Gras, S. L., & Del
528 Rio, D. (2015). The degradation of curcuminoids in a human faecal fermentation model.
529 *International Journal of Food Science and Nutrition*, 66(7),790-796.

530 Vitaglione, P., Barone Lumaga, R., Ferracane, R., Radetsky, I., Mennella, I., Schettino, R., Koder,
531 S., Shimoni, E., & Fogliano, V. (2012). Curcumin bioavailability from enriched bread: the
532 effect of microencapsulated ingredients. *Journal of Agricultural and Food Chemistry*,
533 60(13), 3357-3366.

534 Wang, Y., Lu, Z., Lv, F., & Bie, X. (2009). Study on microencapsulation of curcumin pigments by
535 spray drying. *European Food Research and Technology*, 229(3), 391-396.

536 Wang, Y. J., Pan, M. H., Cheng, A. L., Lin, L. I., Ho, Y. S., Hsieh, C. Y., & Lin, J. K. (1997).
537 Stability of curcumin in buffer solutions and characterization of its degradation products.
538 *Journal of Pharmaceutical and Biomedical Analysis*, 15(12), 1867-1876.

539 Zou, L., Liu, W., Liu, C., Xiao, H., & McClements, D. J. (2015). Utilizing food matrix effects to
540 enhance nutraceutical bioavailability: increase of curcumin bioaccessibility using excipient
541 emulsions. *Journal of Agricultural and Food Chemistry*, 63(7), 2052-2062.

542

543

544 **Table 1** Curcuminoids in oleoresin and in curcuminoid-rich ingredients. Values are expressed as mg
 545 of curcumin, demethoxycurcumin and bisdemethoxycurcumin per gram of sample. The relative
 546 percentage of each curcuminoid on the total curcuminoids is reported in the bracket. The total
 547 curcuminoids content (% w/w in respect to the weight of sample) and the WSI of curcuminoids in
 548 each ingredient (expressed as total curcuminoid concentration in a saturated aqueous solution,
 549 $\mu\text{g/mL}$) are also reported.

550

	Curcumin (mg/g)	Demethoxy- Curcumin (mg/g)	Bisdemethoxy- Curcumin (mg/g)	<i>Total curcuminoids content (%)</i>	<i>WSI $\mu\text{g/mL}$</i>
Oleoresin	160 ± 7 (66%)	41.2 ± 0.8 (17%)	39.6 ± 1.1 (17%)	24	-
GA/MD	6.20 ± 0.26 (63%)	1.75 ± 0.04 (18%)	1.89 ± 0.02 (19%)	1	82
Turmeric	14.4 ± 0.3 (71%)	3.26 ± 0.05 (16%)	2.49 ± 0.05 (12%)	2	1.8
Meriva®	168 ± 6 (82%)	27.3 ± 1.8 (13%)	8.69 ± 0.04 (5%)	20	2.1

551

552

553 **Table 2** Effect of the *in vitro* gastro-intestinal digestion on curcuminoid content of curcuminoid-rich
 554 ingredients Values are expressed as mg of total curcuminoids per gram of digested ingredient. Percentage of
 555 degradation of the digested sample compared to the undigested one is reported in the bracket. Different
 556 letters represent significant differences within the same sample (column) ($p < 0.05$).
 557

	GA/MD (mg/g)	Turmeric (mg/g)	Meriva® (mg/g)
Undigested	10.3±0.8 ^a	20.1±0.4 ^a	204±8 ^a
Gastric phase	8.22±1.13 ^b (-20%)	17.3±1.3 ^{ab} (-14%)	186±15 ^{ab} (-9%)
Intestinal phase	7.05±0.77 ^b (-32%)	16.8±1.2 ^b (-16%)	169±7 ^b (-17%)

558

559

560 **Table 3** Effect of an *in vitro* gastro-intestinal digestion on curcuminoid content in foods. Values are
 561 expressed as μg of total curcuminoids per gram of digested food. Percentage of variations of the digested
 562 sample compared to the undigested one is reported in the bracket. Different letters represent significant
 563 differences within the same sample (column) ($p < 0.05$).
 564

	Rice-GA/MD	Rice-turmeric	Yogurt-GA/MD
	($\mu\text{g/g}$)	($\mu\text{g/g}$)	($\mu\text{g/g}$)
Undigested sample	418 \pm 27 ^a	426 \pm 64 ^a	478 \pm 17 ^a
Gastric phase	347 \pm 8 ^{ab} (-17%)	344 \pm 26 ^{ab} (-19%)	429 \pm 29 ^a (-10%)
Intestinal phase	304 \pm 6 ^b (-27%)	289 \pm 25 ^b (-32%)	358 \pm 41 ^b (-25%)

565

566



567 **Figure 1.** Fe-SEM image of the microencapsulated ingredient (GA/MD). Panel A) magnification: 5000x.
568 Panel B) magnification: 20000x.

569 **Figure 2.** Bioaccessibility of curcuminoids after the *in vitro* gastro-intestinal digestion of the curcuminoid-
570 rich ingredients. Values are expressed as percentage of soluble (bioaccessible) and insoluble (non-
571 bioaccessible) curcuminoids in respect to the total content in digested sample.


572 **Figure 3.** Effect of 5-h microbial biotransformation on the curcuminoid content of the curcuminoid-rich
573 ingredients. Data are expressed as the percentage of variation of total curcuminoids at t_{300} compared to those
574 at t_0 in ascending, transverse and descending colon. For each colon tract, values accompanied by the same
575 letter are not significantly different.

576 **Figure 4.** Bioaccessibility of curcuminoids in foods after the *in vitro* gastro-intestinal digestion. Values are
577 expressed as percentage of soluble (bio-accessible) and insoluble (non-bioaccessible) fraction in respect to
578 the total content of digested food.

579 **Figure 5.** Effect of 5-h microbial biotransformation on curcuminoid content in rice. Data are expressed as
580 the percentage of variation of total curcuminoids at t_{300} compared to those at t_0 in ascending, transverse and
581 descending colon. For each intestinal tract, values accompanied by the same letter are not significantly
582 different.




GA/MD




■ soluble ■ insoluble

Turmeric




■ soluble ■ insoluble


Meriva®



■ soluble ■ insoluble




Rice-GA/MD




■ soluble ■ insoluble

Rice-turmeric



■ soluble ■ insoluble

Yogurt-GA/MD



■ soluble ■ insoluble

